Recognition of DNA:RNA hybrids by a novel neomycin-methidium derivative

CARB 44

Nicholas N. Shaw, nshaw@clemson.edu, Hongjuan Xi, hxi@clemson.edu, and Dev P. Arya, dparya@clemson.edu. Department of Chemistry, Clemson University, H. L , Hunter Laboratories, Clemson, SC 29634
DNA:RNA hybrid structures are of significant interest due to the key role they play in a number of biological processes such as translation, reverse translation and the catalytic cycle of telomerase. However, few reported attempts have been made to target the unique structure of the DNA:RNA hybrid. Ethidium bromide, an intercalator, has been shown to specifically bind DNA:RNA hybrids when in competition with various nucleic acid structures. Our group has previously shown the unique ability of neomycin to bind nucleic acid structures of A-form conformation. Through the direct conjugation of neomycin to an ethidium bromide derivative, a novel neomycin conjugate has been developed to specifically target DNA:RNA hybrid, A-form, structures. Design, synthesis and thermodynamic binding characterization of a novel neomycin-methidium derivative capable of specifically targeting DNA:RNA hybrid structures will be presented.

 

General Posters
6:00 PM-8:00 PM, Tuesday, March 27, 2007 Hyatt Regency Chicago -- Riverside Center, Poster

Division of Carbohydrate Chemistry

The 233rd ACS National Meeting, Chicago, IL, March 25-29, 2007